DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)-Reference-Cited by-同舟云学术

DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)

Published:2018-03 Issue:11 Volume:71 Page:A1825
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Cannon Christopher P.,McGuire Darren,Pratley Richard,Dagogo-Jack Samuel,Mancuso James,Huyck Susan,Charbonnel Bernard,Shih Weichung,Gallo Silvina,Masiukiewicz Urszula,Golm Gregory,Francesco Cosentino,Lauring Brett,Terra Steven

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-10-25

2. Cardiovascular Outcome Trials with Glucose-Lowering Drugs;Current Cardiology Reports;2021-06-03

3. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?;American Journal of Therapeutics;2020-03-18

4. Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk;Diabetes, Obesity and Metabolism;2020-03-02

5. Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry;Diabetes, Obesity and Metabolism;2019-08